TOP-REAL Study: Innovative Digital Monitoring for HER2-Positive Breast Cancer
Introduction
The TOP-REAL study is a groundbreaking international initiative aimed at exploring whether digital monitoring can facilitate early detection of toxicities in patients with HER2-positive metastatic breast cancer. Conducted by Solti in collaboration with Unicancer in France and WSG in Germany, the study was presented at the ESMO AI Digital Oncology congress in Barcelona on November 20, 2026.
Objective of the Study
This innovative research seeks to implement a proactive monitoring model to assess changes in symptoms and physiological conditions between hospital visits. By doing so, researchers hope to determine whether early intervention can prevent toxicities from interrupting the administration of trastuzumab deruxtecan (T-DXd) combined with pertuzumab, one of the most effective treatment regimens for this disease.
Methodology
Featuring the monitoring of around 300 patients across 60 sites in Spain, France, and Germany, the study is designed to produce robust data that reflects real-world medical practices. Notably, it includes underrepresented patient profiles, such as those with active brain metastases or an ECOG performance score of 2, which are often excluded from pivotal trials.
Patient-reported outcomes (ePRO), pulse oximetry, and continuous physiological data collected through smartwatches will provide insights into the patient's condition in real-time. This comprehensive monitoring approach is intended to alert healthcare providers about any concerning changes, enabling earlier clinical evaluation and intervention.
Importance of Managing Toxicities
The efficacy of HER2-positive breast cancer treatments has raised the necessity to manage treatment-related toxicities effectively. Side effects can significantly impact a patient’s quality of life, with potential repercussions that may necessitate dosing alterations, treatment delays, or even discontinuation. Dr. Cristina Saura, the principal investigator of the study, underscores the critical need for not only improving clinical outcomes but also enhancing patients' quality of life during therapy.
Exploring Specific Toxicities
The study places a specific focus on monitoring interstitial lung disease and pneumonia associated with T-DXd. Regular oxygen saturation measurements via pulse oximeters and periodic exercise testing will explore any changes that could warrant early medical assessment. This innovative approach represents a new paradigm in clinical monitoring, where proactive measures can significantly improve patient care and treatment outcomes.
Envisioning a Real-World Application
The TOP-REAL study aims to extend the benefits of advanced treatments such as T-DXd combined with pertuzumab to a broader patient population by closely analyzing their experiences and side effects. Dr. Santiago Escrivà elaborated on the necessity of understanding how such treatments can be tailored to various patient profiles while optimizing toxicity management through digital tracking tools.
Impact on Quality of Life
The study also emphasizes the evaluation of quality of life related to health over time leading up to subsequent therapies. It employs the EORTC QLQ-C30 questionnaire, which encompasses multiple dimensions of patient quality of life assessments, to gain a comprehensive understanding of how the treatment affects everyday living.
A Collaborative European Effort
Prof. Nadia Harbeck, another key investigator, highlighted the international collaboration's significance in translating research findings into clinical practice. TOP-REAL's multifaceted approach not only focuses on toxicity management but also investigates the feasibility and safety of reshaping treatment protocols for selected patients. The integration of tumor biopsies and blood samples for biomarker analysis is also a critical part of the study design.
Conclusion
TOP-REAL represents a transformative approach to managing HER2-positive metastatic breast cancer treatment. By leveraging digital tools for patient monitoring, the study endeavors to enhance patient experiences, improve outcomes, and ultimately, offer hope in the ongoing battle against cancer. As researchers continue to unveil the findings from this ambitious initiative, it undoubtedly sets a precedent for how future clinical trials can be conducted, ensuring that innovation and patient-centered care go hand in hand.